Choosing the right biologic treatment for moderate-to-severe plaque psoriasis: the impact of comorbidities
Expert Review of Clinical Pharmacology · 02.04.2024 · 17 (4) · 363-379
DOI: 10.1080/17512433.2024.2340552 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Expert Review of Clinical Pharmacology, online erschienen am 11.04.2024. Verfasst von Laura Mateu-Arrom und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Institut d'Investigació Biomèdica Sant Pau (IIB SANT PAU), Universitat Autònoma de B…. Hauptthemen laut MEDLINE: Psoriasis, Arthritis, Psoriatic, Inflammatory Bowel Diseases, Biological Products. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 222 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: Psoriasis is a chronic inflammatory skin disease often associated with several comorbidities, such as psoriatic arthritis, inflammatory bowel disease, obesity, diabetes mellitus or cardiovascular diseases, infections, or cancer, among others. With the progressive aging of the population, a growing number of patients with psoriasis can be expected to present multiple comorbidities. Currently, there is a wide range of biological treatments available for moderate to severe psoriasis, including tumor necrosis alpha (TNF) inhibitors, IL12/23 inhibitor, IL17 inhibitors, and IL23 inhibitors. AREAS COVERED: This review aims to describe the specific characteristics of these drugs in relation to psoriasis comorbidities, in order to facilitate decision-making in clinical practice. EXPERT OPINION: Some of the biological treatments can influence comorbidities, in some cases even improving them. Therefore, comorbidities are a key factor when deciding on one biological treatment over another. The development of new drugs is expanding the therapeutic arsenal for psoriasis. A high level of expertise in the field with a detailed knowledge of the characteristics of every drug is imperative to provide personalized medicine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Institut d'Investigació Biomèdica Sant Pau (IIB SANT PAU), Universitat Autònoma de Barcelona, Barcelona, Spain.
ORCID-Profile: Laura Mateu-Arrom, Lluis Puig
Zitieren
APA
Mateu-Arrom, L., & Puig, L. (2024). Choosing the right biologic treatment for moderate-to-severe plaque psoriasis: the impact of comorbidities. Expert Review of Clinical Pharmacology, 17(4), 363-379. https://doi.org/10.1080/17512433.2024.2340552
Vancouver
Mateu-Arrom L, Puig L. Choosing the right biologic treatment for moderate-to-severe plaque psoriasis: the impact of comorbidities. Expert Review of Clinical Pharmacology. 2024;17(4):363-379. doi:10.1080/17512433.2024.2340552
BibTeX
@article{MateuArrom2024,
author = {Mateu-Arrom, Laura and Puig, Lluis},
title = {Choosing the right biologic treatment for moderate-to-severe plaque psoriasis: the impact of comorbidities},
journal = {Expert Review of Clinical Pharmacology},
year = {2024},
volume = {17},
number = {4},
pages = {363--379},
doi = {10.1080/17512433.2024.2340552}
}
EUVIMED